Lumos Diagnostics Holdings Ltd (ASX: LDX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Lumos Diagnostics Holdings Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Lumos Diagnostics Holdings Ltd (ASX: LDX)
Latest News
Healthcare Shares
2 ASX healthcare shares rocketing over 16% on Big US news
Healthcare Shares
3 ASX healthcare shares rocketing 20% to 100% today
Healthcare Shares
Lumos Diagnostics share price rockets 1,036% in 2 days on FDA news
Ask a Fund Manager
Expert reveals one IPO he's absolutely pumped about. When will it hit the ASX?
Ask a Fund Manager
2 small-cap ASX shares to handsomely reward patient investors
Coronavirus News
Why are ASX COVID test shares climbing today?
Healthcare Shares
The Lumos Diagnostics (ASX:LDX) share price is soaring another 8% today. Here's why
Healthcare Shares
Why the Lumos Diagnostics (ASX:LDX) share price is up 15% today
Share Gainers
AnteoTech (ASX:ADO) share price gains 42% in a week amid RAT race
Healthcare Shares
Lumos Diagnostics (ASX:LDX) share price climbs amid RAT mania
Share Gainers
Lumos Diagnostics (ASX:LDX) share price up 9% on evaluation update
IPOs
Lumos Diagnostics (ASX:LDX) share price adds 9% on IPO, raising $63m
LDX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services, and it operates across two geographical regions, the United States and Australia. and the majority of revenue is generated from the United States.
LDX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
04 Nov 2024 | $0.04 | $0.00 | 0.00% | 428,447 | $0.03 | $0.04 | $0.03 |
01 Nov 2024 | $0.04 | $0.00 | 0.00% | 179,368 | $0.04 | $0.04 | $0.04 |
31 Oct 2024 | $0.04 | $0.00 | 0.00% | 1,549,975 | $0.03 | $0.04 | $0.03 |
30 Oct 2024 | $0.03 | $0.00 | 0.00% | 2,638,912 | $0.04 | $0.04 | $0.03 |
29 Oct 2024 | $0.04 | $0.00 | 0.00% | 9,120,687 | $0.04 | $0.04 | $0.04 |
28 Oct 2024 | $0.04 | $0.00 | 0.00% | 753,239 | $0.04 | $0.04 | $0.04 |
25 Oct 2024 | $0.04 | $0.00 | 0.00% | 2,196,922 | $0.04 | $0.04 | $0.04 |
24 Oct 2024 | $0.04 | $0.00 | 0.00% | 1,133,913 | $0.04 | $0.04 | $0.04 |
23 Oct 2024 | $0.04 | $0.00 | 0.00% | 1,172,276 | $0.04 | $0.04 | $0.04 |
22 Oct 2024 | $0.04 | $0.00 | 0.00% | 805,103 | $0.05 | $0.05 | $0.04 |
21 Oct 2024 | $0.05 | $0.00 | 0.00% | 3,081,477 | $0.05 | $0.05 | $0.04 |
18 Oct 2024 | $0.05 | $0.00 | 0.00% | 1,254,254 | $0.04 | $0.05 | $0.04 |
17 Oct 2024 | $0.05 | $0.00 | 0.00% | 2,012,031 | $0.05 | $0.05 | $0.04 |
16 Oct 2024 | $0.05 | $0.00 | 0.00% | 146,611 | $0.05 | $0.05 | $0.05 |
15 Oct 2024 | $0.05 | $0.00 | 0.00% | 2,494,369 | $0.05 | $0.05 | $0.05 |
14 Oct 2024 | $0.04 | $0.00 | 0.00% | 2,656,139 | $0.05 | $0.05 | $0.04 |
11 Oct 2024 | $0.05 | $0.00 | 0.00% | 3,540,520 | $0.05 | $0.05 | $0.04 |
10 Oct 2024 | $0.05 | $0.00 | 0.00% | 1,259,160 | $0.04 | $0.05 | $0.04 |
09 Oct 2024 | $0.04 | $0.00 | 0.00% | 2,995,571 | $0.04 | $0.05 | $0.04 |
08 Oct 2024 | $0.04 | $0.00 | 0.00% | 3,515,700 | $0.04 | $0.04 | $0.04 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
09 Oct 2024 | Bronwyn Le Grice | Issued | 60,970 | $2,316 |
Rights issue.
|
09 Oct 2024 | Catherine Robson | Issued | 734,940 | $27,927 |
Rights issue.
|
09 Oct 2024 | Samuel Lanyon | Issued | 137,362 | $5,219 |
Rights issue. As per announcement on 10-10-2024
|
11 Jun 2024 | Catherine Robson | Buy | 312,500 | $10,625 |
On-market trade.
|
07 Jun 2024 | Samuel Lanyon | Buy | 250,000 | $7,500 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Ms Bronwyn Joyce Le Grice | Non-Executive Director | Nov 2020 |
Ms Grice has more than 18 years of executive experience in the health technology sector spanning commercialization, venture capital, corporate development, capital raising and industry advocacy. Formerly an Investment Director with healthcare investment firm, BioScience Managers, Ms. Le Grice managed over $65M of private and public equity capital raisings and was involved in over $30M of portfolio investments. In 2017, she founded ANDHealth, Australia's dedicated digital health accelerator and commercialization support organization which has led to growth within Australia's nascent digital health sector. Ms. Le Grice holds a number of health, technology and innovation advisory roles in Australia and internationally, and is a Director of ANDHealth Pty Ltd. She is Chair of the Disclosure Committee and member of Risk Committee.
|
Ms Catherine Robson | Non-Executive Director | Dec 2020 |
Ms Robson has more than 20 years of experience in management, finance and investment. Ms. Robson currently chairs the Board of fully owned subsidiary Equity Trustees Superannuation Limited. Ms. Robson's other Board appointments include serving as a Non-Executive Director for Australia's customer owned bank, Newcastle Greater Mutual Group, where she chairs the Audit Committee. She is Chair of the Risk Committee.
|
Ms Lawrence Mehren | Non-Executive Deputy ChairmanNon-Executive Director | Dec 2020 |
Mr Mehren served as President and Chief Executive Officer as well as a Director of Accelerate Diagnostics from 2012 to 2020. During his tenure, the company developed and launched its Accelerate Pheno instrument. Prior to this, Mr. Mehren was the Head of Global Business for Ventana Medical Systems and Roche Tissue Diagnostics managing its four business units. He also held global leadership positions with Ventana including Senior Vice President of Emerging Businesses and Chief Financial Officer. Mr. Mehren was also Managing Director, Partner and Head of P&M Corporate Finance's life sciences practice.
|
Mr Samuel Ross Garland Lanyon | Non-Executive ChairmanNon-Executive Director | Jun 2022 |
Mr Lanyon has more than 25 years of experience in strategy, sales and operations with a track record in the global commercialization of technology rich healthcare products. Mr. Lanyon currently serves as Executive Director and co-founder of Planet Innovation and a Non-Executive Director of Paragon Funds Management. Previously, Mr. Lanyon held international executive roles with Leica Microsystems, part of Danaher Corporation, and Vision Systems Ltd where he was responsible for establishing Vision Biosystem's sales, marketing, and service operations throughout the EU, Middle East, Latin America, and Asia Pacific. He is member of the Disclosure Committee and Risk Committee.
|
Mr Doug Ward | Chief Executive OfficerManaging Director | Jun 2022 |
Mr Ward has more than 30 years of biotech and medical technology experience at global healthcare companies including Roche, GE, Siemens, Bayer, Chiron and Hologic. During his career, Mr. Ward has held executive positions where he developed and implemented novel business strategies and introduced products to the practice of medicine. Prior to joining Lumos, he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in women's healthcare to improve clinical results. Mr. Ward also served as the CEO of Personal Genome Diagnostics (PGDx) where he led the organization's transformation from a clinical laboratory testing service into a fully functional molecular invitro diagnostics (IVD) company. He brings experience across all company functions, including Commercial Leadership, R&D, Operations, Quality, Regulatory, Service, and Support.
|
Ms Melanie Jaye Leydin | Chief Financial OfficerCompany Secretary |
-
|
|
Ms Tracy Weimar | Company Secretary |
-
|
|
Barrie Lambert | Chief Financial Officer |
-
|
|
Melanie Jaye Leydin | Chief Financial OfficerCompany Secretary |
-
|
|
Sacha Dopheide | Chief Technology Officer |
-
|
|
Tracy Weimar | Company Secretary |
-
|
|
Sarah Glubka | Senior Director of Human Resources |
-
|
|
Annie Bell | Senior Director of Medical Affairs |
-
|
|
Paul Kase | Senior Vice President Commercial Operations |
-
|
|
Mike Raymundo | Vice President of Product Development |
-
|
|
Jon Gary | Vice President of Research and Development |
-
|
|
Sue Hibbeln | Vice President Quality and Regulatory Affairs |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 83,463,862 | 17.34% |
Planet Innovation Holdings Limited | 68,021,060 | 14.13% |
J P Morgan Nominees Australia Pty Limited | 23,765,171 | 4.94% |
GZ Family Holdings Pty Ltd | 11,860,707 | 2.46% |
Palm Beach Nominees Pty Limited | 11,500,000 | 2.39% |
Mr Lawrence Wing Ming Ho and Mrs Ying Ho | 11,000,000 | 2.29% |
Spiceme Capital Pty Ltd | 10,000,000 | 2.08% |
Mr Kenneth Graham Miller | 5,398,165 | 1.12% |
City Comfort Pty Ltd | 5,102,078 | 1.06% |
Mr Garry Temple | 4,730,809 | 0.98% |
Bowvale Investments Pty Limited | 4,312,095 | 0.90% |
Paranji Super Fund Pty Ltd | 4,000,000 | 0.83% |
Ms Yan Chen | 3,548,868 | 0.74% |
Mr Jordan Edward Duncan Whicker | 3,000,000 | 0.62% |
Colonial First State Inv Ltd | 2,882,383 | 0.60% |
Mr Farouk Ahmed | 2,800,000 | 0.58% |
Pineleaf Pty Limited | 2,782,792 | 0.58% |
Garry Temple Pty Ltd | 2,742,644 | 0.57% |
BNP Paribas Nominees Pty Ltd | 2,729,215 | 0.57% |
Citicorp Nominees Pty Limited | 2,697,268 | 0.56% |